Skip to main content

Table 2 cost-effectiveness comparison

From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

  Utility(QALY) Increased utility Cost($) Increased costs ICER
warfarin 11.07   5317.31   
Rivaroxaban 15.46 4.39 29673.33 24356.02 5548.07
Dabigatran110mg 12.40 1.33 23615.48 18298.17 13758.02
Dabigatran150mg 15.00 3.93 34324.91 29007.60 7381.07
\